double-blind study to compare Fluarix TM with another influenza vaccine. Five open-label, non-randomised studies in high-risk adult populations were performed in selected years from 1995-2000.

The vaccine segment reported 15 per cent Y-o-Y growth, driven by strong growth for Boostrix, Variritix, and Fluarix. In addition, GSK Pharma is intensifying efforts to increase adult immunisation ...

Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine, which was co ...